relenza, page-10

cpg

You hit the nail on the head. Nothing worthwhile posting at the moment, all old materials. Wu, Colman and Von Itzstein engineered zanamivir to be bullet proof against flu mutants. Bit of a waste of time now, 20 years down the track and say that your Relenza is great. The Nature publication might as well appear after the patent runs out, then the World can source zanamivir from generic companies in India.


Its a pity how things turn out, the original venture capitalist, Mark Crosling (foundation CEO) got himself in the bad books with the regulators in this cut throat wheeling and dealing market space. Cpg, I wonder what the current crop of people inside Biota are doing. Surely it does not take an army full of "hanger ons" to do what they are currently doing.


For the $5.00 target, lets hope Biota keeps cancelling more shares.

I am going back to sleep on this one, hopefully we get worthy news the next time I wake up.


Cheers